Navigation Links
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab

ing AMD, with additional mechanisms of action as compared with the various anti-VEGF compounds that dominate the market and fill the pipelines of pharmaceutical and biotech companies alike. Given these highly favorable factors, Sphingomab is extremely well positioned in the AMD arena."

Lpath plans to initiate clinical trials for wet AMD in early 2008.

About Lpath

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomic-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. Lpath's lead product candidate, Sphingomab, is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P), and has demonstrated compelling results in preclinical studies against multiple forms of cancers, against AMD, and against heart failure. Sphingomab is potently anti-angiogenic, yet it has other mechanisms of action that may prove advantageous in the clinical setting. As such, Lpath believes Sphingomab may represent the next generation of anti-angiogenesis-based therapeutics.

Lpath's second product candidate, Lpathomab(TM), is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types.

Lpath's unique ability to generate antibodies against bioactive lipids is based on its patented ImmuneY2(TM) technology. The company intends to apply the ImmuneY2 process to other important lipid-signaling agents, thereby providing a robust pipeline of antibody-based drug candidates. For more information, visit www.lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Post Your Comments:
(Date:9/19/2014)... 19, 2014  For Cloud Pharmaceuticals, Inc., a ... development, partnering is an integral part of its ... new drugs and identify early stage, preclinical, IND, ... their development. The company also partners with funds ... business model, Cloud Pharmaceuticals will be participating in ...
(Date:9/19/2014)... 19, 2014  Diplomat, the nation,s largest independent specialty ... to the Board of Directors on September 15, ... also serve as chair of the Audit Committee. ... accounting, financial, compliance and operating experience in the health ... as chief financial officer, chief operating officer and secretary ...
(Date:9/19/2014)... 2014  Alere Inc. (NYSE: ALR ), ... statement today in support of President Barack Obama,s ... the global leader in rapid diagnostics for infectious disease, ... to address the serious threat of antibiotic resistance. We ... on initiatives to promote the development of rapid point-of-care ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Medical Corporation today announced that it is a winner of ... Premier healthcare alliance . Premier has contracts ... 39 contracted suppliers to receive the Pinnacle Award. Winners are ... drive toward the mutual goal of providing clinical and financial ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... quarterly dividend payment of $0.15 per share to all stockholders owning ... About PDL BioPharma ... enabled the discovery of a new generation of targeted treatments for ...
Cached Medicine Technology:Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 2Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 3
(Date:9/20/2014)... CA (PRWEB) September 20, 2014 On ... receive a $250,000 pediatric cancer research grant from Hyundai ... Loma Linda University Children’s Hospital located on 11234 Anderson ... work of Dr. Kimberley Payne, Associate Professor at Loma ... work focuses on leukemia in children. , ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is being ... with a circulation of approximately 97,000 copies and ... is distributed nationally through a vast social media ... sites and partner outlets. To explore the digital ... , The publication features an exclusive Mediaplanet interview ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... season is coming soon. The high-end fashion designer BellasDress is ... . A lot of sophisticated women like its new items. ... for its high quality clothes. Now, each of its elegant ... 71 percent off. , The company’s cocktail dress assortment ... many fashionable colors. Mary, the company’s sales manager, believes that ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
Breaking Medicine News(10 mins):Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4
... American Jewish World Service (AJWS) has applauded President Barack ... U.S. funding for family planning services provided by overseas NGOs ... , , "President Obama,s decision to roll back ... believe that the only way to stop the spread of ...
... nation,s leading medical transcription school, provides students ... reference tool, Benchmark KB. Developed ... Documentation Integrity (AHDI) and transcription industry technology ... an extensive collection of online medical transcription ...
... 23 The following is a statement by ... on State Department And Foreign Operations: "President Obama ... that harms many and helps no one. ... births and reduce infant mortality, while preventing abortions, ...
... Fatalities have dropped 21%, while population has increased 10%, study ... are safer drivers than they were a decade ago, a ... age of 70 fell 21 percent between 1997 and 2006, ... number of those in this age group. Although the number ...
... decision by President Barack Obama to reverse the ... Justin Rigali, chairman of the U.S. Bishops, Committee ... after President Obama issued the executive order restoring ... abortion in developing nations. Cardinal Rigali,s statement follows."It ...
... he delivers his unique music and message for young cancer ... Jan. 23 Coffey Anderson has never taken his talents ... to "give back" to a worthy cause, especially one involving ... so quickly with volunteers eager to bring their own brand ...
Cached Medicine News:Health News:AJWS Encouraged by Obama Move to Rescind Global Gag Rule 2Health News:Career Step, Leading School In Growing Health Documentation Industry, Adds Online Reference Tool 2Health News:Career Step, Leading School In Growing Health Documentation Industry, Adds Online Reference Tool 3Health News:Elderly Car Crash Deaths Down in Last Decade 2Health News:Elderly Car Crash Deaths Down in Last Decade 3Health News:Elderly Car Crash Deaths Down in Last Decade 4Health News:Country Singer Coffey Anderson to Join Celebs at Valerie Fund Event 2
... an option beyond traditional methods for ... low back pain. The new Orthotrac,Pneumatic ... chronic back pain. In fact, associated ... of application.,The Orthotrac is the only ...
Optical Urethrotome for Telescope 1.9 mm for neonates and children....
Optical Urethrotome for Telescope 2.7 mm for children....
Optical Mini Urethrotome for telescope 3.3 mm, 0...
Medicine Products: